# HuLA immune

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hula-immune

- Industry: Pharmaceuticals
- Headquarters: Tokyo, Japan
- Website: www.hulaimmune.com
- Total disclosed funding: $5.5M
- Latest round: Series B (Mar 11, 2020)
- Investors on record: 2

## About

HuLA immune Inc. is a biotechnology company focused on developing innovative immune therapies aimed at addressing complex health challenges in various sectors, including healthcare and pharmaceuticals.Founded in 2017 and headquartered in Tokyo, Japan, HuLA immune Inc. specializes in cutting-edge immune therapy solutions. The company has engaged in two significant deals, with the latest funding round being a Series B that raised JPY 400 million on March 11, 2020, from investors Mitsubishi UFJ Capital and Osaka University Venture Capital. The total amount raised by the company stands at JPY 400 million, with a current valuation of JPY 2,094.071 million.HuLA immune Inc. specializes in a range of innovative products designed to address specific challenges faced by various industries. Their core offerings focus on delivering advanced technological solutions that enhance operational efficiency and reduce costs for their clients. These products cater primarily to sectors such as manufacturing, logistics, and healthcare, providing tools that streamline processes and improve productivity. The company serves a diverse client base, including small to medium-sized enterprises and large corporations, across geographical markets including North America, Europe, and parts of Asia. End users benefit from improved functionality and user experience, as the products are tailored to meet the distinct requirements of each industry segment they serve.The revenue model for HuLA immune Inc. is structured around a combination of direct sales and strategic partnerships, enabling them to effectively reach both B2B and direct-to-consumer markets. Transactions typically involve a subscription-based pricing plan for ongoing services and support, along with one-time fees for flagship products that offer significant value to clients. Specific examples of these transactions include annual contracts for software solutions that include regular updates and customer support, as well as bespoke packages tailored to the unique needs of larger clients. The company's trademarked offerings are positioned to provide long-term solutions, fostering ongoing relationships with clients and encouraging repeat business through continued service engagement. Overall, the revenue generation strategy emphasizes the importance of sustained client partnerships to drive business growth.HuLA immune Inc. aims to expand its product line with new immune therapies designed for upcoming market needs, although specific release dates have yet to be announced. The company is focused on expanding into new markets, particularly in North America and Europe, by the end of 2023. Recent funding of JPY 400 million will be strategically utilized to support these initiatives, particularly in enhancing research and development capabilities.

## Funding rounds

- Series B, Mar 11, 2020, $3.7M — Mitsubishi UFJ Capital, Osaka University Venture Capital
- Series A, Dec 12, 2018, $1.8M — Mitsubishi UFJ Capital, Osaka University Venture Capital

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A, Series B
- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Series A, Series B